Roundtable: Securing Investment by Demonstrating Scalable iPSC Manufacturing & Early Commercial Credibility
- Sharing real‑world lessons learned from an iPSC developer that unlocked funding by proving manufacturability beyond benchtop scale, including CQA stability, early comparability data, and clear scale‑up rationale
- Highlighting which technical milestones (genomic stability, potency consistency, suspension feasibility, cost‑per‑dose modeling) most effectively shifted investor confidence during due diligence
- Demonstrating how the team aligned CMC, clinical, and commercial assumptions to show a credible path to pivotal readiness, reducing perceived risk, and accelerating successful capital raise